Natco Pharma Limited (NSE:NATCOPHARM) — Market Cap & Net Worth
Market Cap & Net Worth: Natco Pharma Limited (NATCOPHARM)
Natco Pharma Limited (NSE:NATCOPHARM) has a market capitalization of $2.12 Billion (Rs196.26 Billion) as of May 2, 2026. Listed on the NSE stock exchange, this India-based company holds position #6044 globally and #262 in its home market, demonstrating a 2.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Natco Pharma Limited's stock price Rs1095.75 by its total outstanding shares 179109870 (179.11 Million). Analyse Natco Pharma Limited cash flow conversion to see how efficiently the company converts income to cash.
Natco Pharma Limited Market Cap History: 2015 to 2026
Natco Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $1.04 Billion to $2.12 Billion (8.12% CAGR).
Index Memberships
Natco Pharma Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.11 Trillion | 0.19% | #152 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.20 Trillion | 0.07% | #234 of 750 |
Weight: Natco Pharma Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Natco Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Natco Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Natco Pharma Limited's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.09x
Natco Pharma Limited's market cap is 0.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.04 Billion | $10.42 Billion | $1.57 Billion | 0.10x | 0.66x |
| 2017 | $1.75 Billion | $20.20 Billion | $4.86 Billion | 0.09x | 0.36x |
| 2018 | $1.25 Billion | $21.85 Billion | $6.96 Billion | 0.06x | 0.18x |
| 2019 | $1.10 Billion | $20.95 Billion | $6.44 Billion | 0.05x | 0.17x |
| 2020 | $1.81 Billion | $19.15 Billion | $4.61 Billion | 0.09x | 0.39x |
| 2021 | $1.71 Billion | $20.56 Billion | $4.41 Billion | 0.08x | 0.39x |
| 2022 | $1.07 Billion | $19.46 Billion | $1.70 Billion | 0.05x | 0.63x |
| 2023 | $1.56 Billion | $27.09 Billion | $7.15 Billion | 0.06x | 0.22x |
| 2024 | $2.69 Billion | $40.02 Billion | $13.88 Billion | 0.07x | 0.19x |
| 2025 | $1.75 Billion | $44.32 Billion | $18.85 Billion | 0.04x | 0.09x |
Competitor Companies of NATCOPHARM by Market Capitalization
Companies near Natco Pharma Limited in the global market cap rankings as of May 2, 2026.
Key companies related to Natco Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Natco Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Natco Pharma Limited's market cap moved from $1.04 Billion to $ 2.12 Billion, with a yearly change of 8.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs2.12 Billion | +21.34% |
| 2025 | Rs1.75 Billion | -34.91% |
| 2024 | Rs2.69 Billion | +71.72% |
| 2023 | Rs1.56 Billion | +46.21% |
| 2022 | Rs1.07 Billion | -37.35% |
| 2021 | Rs1.71 Billion | -5.57% |
| 2020 | Rs1.81 Billion | +64.02% |
| 2019 | Rs1.10 Billion | -11.63% |
| 2018 | Rs1.25 Billion | -28.51% |
| 2017 | Rs1.75 Billion | +67.48% |
| 2016 | Rs1.04 Billion | +0.45% |
| 2015 | Rs1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Natco Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.12 Billion USD |
| MoneyControl | $2.12 Billion USD |
| MarketWatch | $2.12 Billion USD |
| marketcap.company | $2.12 Billion USD |
| Reuters | $2.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more